| abstract |
Disclosed herein are octahydroquinoline and octahydroisoquinoline compounds of formula (I), wherein the variables are defined in the specification, and the use thereof in the treatment of diseases caused by 11-beta-hydroxysteroid dehydrogenase type 1 (11-beta-HSD1)-associated disorders such as glaucoma, elevated ocular pressure, metabolic disorders, obesity, metabolic syndrome, dyslipidemia, hypertension, diabetes, atherosclerosis, Cushing's syndrome, psoriasis, rheumatoid arthritis, cognitive disorders, Alzheimer's disease or neurodegeneration, Exemplary embodiments of Formula (I) include: 5,6-dichloro-2-[5-(octahydroisoquinolin-2-yl)-5-oxopentyl]isoindole-1,3-dione; 1-[4-(octahydroisoquinolin-2-yl)-4-oxobutyl]-3,4-diphenylpyrrole-2,5-dione; (2R,6S)-4-[5-(octahydroquinolin-1-yl)-5-oxopentyl]-4-azatricyclo[5.2.2.0(2,6)]undec-8-ene-3,5-dione; and (3aS,7aR)-2-[3-(octahydroquinolin-1-yl)-3-oxopropyl]hexahydroisoindole-1,3-dione. |